This site is intended for
Healthcare Providers Only

EXPAREL®

The only single-dose local analgesic that provides up to
72 hours of postsurgical pain control*1,2


The EXPAREL® Difference

One intraoperative dose provides up to three days of analgesia with reduced opioid requirements*†1,2


Learn About EXPAREL®

EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.1


EXPAREL Infiltration Video for an Open Colectomy by Colorectal Surgeon Stephen Cohen MD, FACS, FASCRS.

Learn More About EXPAREL

Colorectal Surgeon Stephen Cohen MD, FACS, FASCRS demonstrates his EXPAREL infiltration technique during an Open Colectomy procedure.

*Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures; additional studies are underway to further demonstrate the safety and efficacy in other procedures.
The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.


To report an adverse event, e-mail drugsafety@pacira.com or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727).

EXPAREL Clinical Studies

EXPAREL Case Studies

Read a review discussing the role of EXPAREL as the foundation of a multimodal approach to pain management in two case studies. > View Now


Schedule a visit with an EXPAREL Sales Representative

Request a Representative

Schedule a visit with an EXPAREL Sales Representative. > Request a Rep


Sign up to receive updates on EXPAREL

Sign Up

Sign up to receive updates on EXPAREL. > Sign Up


These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.

References:

  1. EXPAREL [prescribing information]. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2011.
  2. Gorfine SR, Onel E, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Diseases of the Colon & Rectum. 2011;54(12):1552-1559.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.


Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.


Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.


In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.

EXPAREL® Sign Up


Sign up to receive updates on EXPAREL.

Required*

First name*

Last name*

E-mail*

ZIP code*

Providing the optional information about you below enables us to provide information geared to your needs.

Specialty




Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy.

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.

EXPAREL® E-mail


Required*

Your name:*

Your colleague's name:*

Your colleague's e-mail address:*

To learn about our use of your information and your rights, please consult our Privacy Policy.

Your email has been sent.
Thank you!

The email address you entered was invalid.

Unfortunately, your email could not be sent at this time.